Neobe Therapeutics

Capital Raising · EMEA

mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).

Capital Raising · EMEA

SK pharmteco announced a $200M+ investment plan over five years to expand CDMO (contract development and manufacturing organization) capabilities and infrastructure.

Leadership Change · EMEA

Harbour BioMed (HKEX: 02142) appointed Vivian Feng as Head of External Collaboration, a new senior role overseeing partnerships with external parties.

Geographic Expansion · EMEA

Bio-Techne is expanding its GMP manufacturing network with a new facility in Bristol, UK, to scale cell therapy development capabilities alongside existing North American operations.

Product Launch · EMEA

AviadoBio has presented Phase 1/2 trial data for AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), showing dose-dependent increases in cerebrospinal fluid progranulin levels across four ascending doses.

Product Launch · EMEA

Biogen announced 52-week Phase 2 results for litifilimab in cutaneous lupus erythematosus (CLE), demonstrating rapid and durable efficacy. Data supports potential first-in-class therapy positioning. Results presented at EADV 2026 Congress in Vienna. Ongoing Phase 2/3 AMETHYST study progressing.